Joseph Alvarnas, MD: Well, this has been a great discussion. Before we end, I’d like to ask the panelists for any additional insights regarding their expectation of value-based care in the oncology healthcare setting. Dr Carlson?
Robert Carlson, MD: I always struggle when we talk about value-based care, because value means so many different things to so many different people. Even for individuals, it depends on the context and what we’re talking about in terms of what value really means. My definition of value, when it comes to oncology care, is really whatever the patient tells me it is and that’s what we should focus on. For some patients, that may be finances. For some patients, that may be survival. For some, it may be whether or not they retain the ability to speak after their laryngeal cancer is treated. It can mean many, many different things. So, let the patient tell me what value means, and I’ll accept that definition and work to achieve value for them.
Joseph Alvarnas, MD: Miss Carpenter?
Elizabeth Carpenter: Something that you talked about earlier today was value frameworks and how they are entering into the system. And at Avalere Health, we’ve been partnering with FasterCures, because we’ve looked at value frameworks and not felt like the patient voice has really been represented. So, we are working on a patient-perspective value framework that’s going to take into account feedback from hundreds of patients and stakeholders from across the healthcare system. I would stay tuned for that.
Joseph Alvarnas, MD: Beautiful. And Dr Fox?
John Fox, MD: There’s a new paradigm that the CMMI and the Oncology Care Model are promulgating, and that is physicians being at risk for the total cost of care for cancer patients. I think that for too long, physicians have been insulated from the cost of healthcare, and now they’re actively having discussions about that driven by these value frameworks—including the ASCO Value Framework and the NCCN Evidence Blocks. I think that’s a good thing because it will help get onto the table not only the financial issues that patients face, but also the benefits and risks of the therapies they receive. That’s where the real value is. I agree with Bob that a clear discussion of all the available treatment options and what they cost and what the side effects are is really where we need to go. And I think the patients will drive that, but they need the physicians’ help; they can’t do that in a vacuum.
Joseph Alvarnas, MD: Wonderful. Thank you all. On behalf of our panel, we’d like to thank you for following the Spring 2017 Oncology Stakeholder Summit Series. We hope you found this Peer Exchange® informative, and we hope you will join us as the series continues. Thank you.
Specialty Pharmacists at the Forefront: Elevating Care for Rare Diseases
May 1st 2024In the US, a disease is considered rare when it affects fewer than 200,000 persons, or 1 in every 1500 individuals, with an estimated total of 25 to 30 million Americans overall living with a rare disease at any given time.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
BRCA-Like Classification May Be a Useful Biomarker for Olaparib Response in Ovarian Cancer
May 1st 2024Adding olaparib to maintenance therapy with bevacizumab was associated with significantly longer survival for patients with ovarian cancer whose tumors have a BRCA-like genomic profile, but not among those with non-BRCA-like tumors, a study found.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
The Federal Trade Commission (FTC) issued letters to 10 companies to warn them that certain drug patents were improperly listed; the US Department of Agriculture (USDA) will begin testing ground beef for bird flu particles; rural Americans are more likely to die early from 1 of the 5 leading causes of death than those who live in urban areas.
Read More
Diving Deep Into Specialty Pharmacy: Insights and Forecasts From IQVIA’s Doug Long
May 1st 2024Doug Long, MBA, vice president of industry relations at IQVIA, covered a bevy of stakeholder investment–related topics in his presentation at AXS24 on trends in specialty pharmacy, chief among them challenges facing the industry, obesity medications, generics and biosimilars, new product launches, and the outlook for the US market.
Read More